News

Patient dosing has begun in the first placebo-controlled clinical trial evaluating Cartesian Therapeutics’ Descartes-08, an investigational CAR T-cell therapy for people with generalized myasthenia gravis (gMG). The Phase 2b randomized controlled trial (RCT), to include up to 30 adults with gMG, follows a crossover design, in which participants…

The Myasthenia Gravis Foundation of America (MGFA) has partnered with Alira Health to relaunch a patient registry for people with myasthenia gravis (MG) that “capitalizes on technological advances,” the nonprofit announced. The initial registry was launched in 2013. The rebranded MGFA Global MG Patient Registry is…

MuSK-CAART, an investigational cell-based therapy being developed to treat myasthenia gravis (MG) patients with anti-MuSK antibodies, eliminated disease-driving B-cells in a mouse model of the disease, a study showed. The findings, some of which were reported previously at a scientific conference, supported Cabaletta Bio’s request for a…

Treatment with an antibody targeting the interleukin-23 (IL-23) protein reduced symptoms and eased inflammation in mouse models of myasthenia gravis (MG), a study found. Evidence suggested the antibody lowers the activation of T-helper 17 (Th17) cells — a cell family implicated in MG and other autoimmune diseases — in…

Ultomiris (ravulizumab-cwvz) has been approved in Canada to treat adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR), the most common type of MG-causing antibody. The announcement came less than a year after Ultomiris was approved for the condition in the U.S., and…

Researchers have identified clinical factors that increase the risk of a post-operative myasthenic crisis (POMC) for patients with myasthenia gravis (MG) who have surgery to remove the thymus gland. Among the risk factors listed are more severe MG with respiratory muscle involvement, pre-operative use of a high dose of pyridostigmine…

Adults with myasthenia gravis (MG) have elevated levels of protein fragments released from T follicular helper (Tfh) cells — an immune cell type involved in the development of autoimmune conditions — in their bloodstream, a study reported. According to researchers, these results suggest that molecules associated with Tfh cells…

Shedding of the muscle-specific tyrosine kinase (MuSK) protein from the surface of muscle cells into the bloodstream could be the reason why anti-MuSK antibodies drive myasthenia gravis (MG) in some cases, according to a study. The protein was found in the blood of healthy mice and people, and was…

The Comirnaty mRNA COVID-19 vaccine was safe and well tolerated in people with myasthenia gravis (MG), a study confirmed. Worsening of MG symptoms after the third vaccine dose occurred in eight of the 113 study participants (7.1%) who were all successfully treated with standard immunoglobulins (IVIG). While…

A new mathematical tool that combines factors such as age at disease onset, sex, and clinical test results, could predict with high accuracy the risk of converting from ocular myasthenia gravis to the generalized form of the disease, a recent study reported. The study, “Dynamic…